University of Texas Rio Grande Valley

ScholarWorks @ UTRGV
School of Medicine Publications and
Presentations

School of Medicine

8-2016

Genome-wide significant loci for addiction and anxiety
Karen Hodgson
Laura Almasy
The University of Texas Rio Grande Valley

Emma E. M. Knowles
Jack W. Kent Jr.
Joanne E. Curran
The University of Texas Rio Grande Valley

See next page for additional authors

Follow this and additional works at: https://scholarworks.utrgv.edu/som_pub
Part of the Communication Sciences and Disorders Commons

Recommended Citation
Hodgson, K., Almasy, L., Knowles, E. E. M., Kent, J. W., Curran, J. E., Dyer, T. D., Göring, H. H. H., Olvera, R.
L., Fox, P. T., Pearlson, G. D., Krystal, J. H., Duggirala, R., Blangero, J., & Glahn, D. C. (2016). Genome-wide
significant loci for addiction and anxiety. European Psychiatry, 36, 47–54. https://doi.org/10.1016/
j.eurpsy.2016.03.004

This Article is brought to you for free and open access by the School of Medicine at ScholarWorks @ UTRGV. It has
been accepted for inclusion in School of Medicine Publications and Presentations by an authorized administrator
of ScholarWorks @ UTRGV. For more information, please contact justin.white@utrgv.edu,
william.flores01@utrgv.edu.

Authors
Karen Hodgson, Laura Almasy, Emma E. M. Knowles, Jack W. Kent Jr., Joanne E. Curran, Thomas D. Dyer,
Harald H. H. Goring, Rene L. Olvera, Peter T. Fox, Godfrey D. Pearlson, J. H. Krystal, Ravindranath
Duggirala, John Blangero, and David C. Glahn

This article is available at ScholarWorks @ UTRGV: https://scholarworks.utrgv.edu/som_pub/125

HHS Public Access
Author manuscript
Author Manuscript

Eur Psychiatry. Author manuscript; available in PMC 2017 June 26.
Published in final edited form as:
Eur Psychiatry. 2016 August ; 36: 47–54. doi:10.1016/j.eurpsy.2016.03.004.

Genome-wide significant loci for addiction and anxiety
K. Hodgsona,*, L. Almasyb, E.E.M. Knowlesa, J.W. Kentc, J.E. Curranb, T.D. Dyerb, H.H.H.
Göringb, R.L. Olverad, P.T. Foxe,f, G.D. Pearlsona,g,h, J.H. Krystala,h,i,j, R. Duggiralab, J.
Blangerob, and D.C. Glahna,g
aDepartment

of psychiatry, Yale University, School of Medicine, New Haven, CT, USA

bSouth

Author Manuscript

Texas Diabetes and Obesity Institute, University of Texas, Rio Grande Valley School of
Medicine, Brownsville, TX, USA

cDepartment

of Genetics, Texas Biomedical Research Institute, San Antonio, TX, USA

dDepartment

of Psychiatry, University of Texas Health Science Center, San Antonio, TX, USA

eResearch
fSouth
gOlin

Imaging Institute, University of Texas Health Science Center, San Antonio, TX, USA

Texas Veterans Health System, 7400, Merton Minter, San Antonio, TX, USA

Neuropsychiatric Research Center, Institute of Living, Hartford Hospital, Hartford, CT, USA

hDepartment

of Neurobiology, Yale University School of Medicine, New Haven, CT, USA

iClinical

Neuroscience Division, VA National Center for PTSD, VA Connecticut Healthcare
System, West Haven, CT, USA

Author Manuscript

jPsychiatry

Services, Yale-New Haven Hospital, New Haven, CT, USA

Abstract
Background—Psychiatric comorbidity is common among individuals with addictive disorders,
with patients frequently suffering from anxiety disorders. While the genetic architecture of
comorbid addictive and anxiety disorders remains unclear, elucidating the genes involved could
provide important insights into the underlying etiology.

Author Manuscript

Methods—Here we examine a sample of 1284 Mexican-Americans from randomly selected
extended pedigrees. Variance decomposition methods were used to examine the role of genetics in
addiction phenotypes (lifetime history of alcohol dependence, drug dependence or chronic
smoking) and various forms of clinically relevant anxiety. Genome-wide univariate and bivariate
linkage scans were conducted to localize the chromosomal regions influencing these traits.
Results—Addiction phenotypes and anxiety were shown to be heritable and univariate genomewide linkage scans revealed significant quantitative trait loci for drug dependence (14q13.2–q21.2,
LOD = 3.322) and a broad anxiety phenotype (12q24.32–q24.33, LOD = 2.918). Significant
positive genetic correlations were observed between anxiety and each of the addiction subtypes
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(ρg = 0.550–0.655) and further investigation with bivariate linkage analyses identified significant
pleiotropic signals for alcohol dependence-anxiety (9q33.1–q33.2, LOD = 3.054) and drug
dependence-anxiety (18p11.23–p11.22, LOD = 3.425).
Conclusions—This study confirms the shared genetic underpinnings of addiction and anxiety
and identifies genomic loci involved in the etiology of these comorbid disorders. The linkage
signal for anxiety on 12q24 spans the location of TMEM132D, an emerging gene of interest from
previous GWAS of anxiety traits, whilst the bivariate linkage signal identified for anxiety-alcohol
on 9q33 peak coincides with a region where rare CNVs have been associated with psychiatric
disorders. Other signals identified implicate novel regions of the genome in addiction genetics.
Keywords
Addiction; Anxiety; Comorbidity; Pleiotropy
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1. Introduction

Author Manuscript

Amongst individuals addicted to licit and illicit substances, the prevalence of comorbid
psychiatric illnesses is high. In particular, epidemiological evidence for the pattern of
comorbidity between addiction and anxiety is well established [1]; in addicted populations,
there is a significant increase in the risk for anxiety disorders, even when covarying for
demographic characteristics and other psychiatric diagnoses [2,3]. For example, among
individuals with alcohol dependence the risk of panic disorder and posttraumatic stress
disorder are doubled and that for generalized anxiety disorder is four times the population
risk [4]. As the severity of substance misuse increases, so does the observed rate of anxiety
comorbidity [2,5]. Psychiatric comorbidities are also associated with poorer outcomes
among individuals with addictive disorders, including more severe symptomatology, greater
social and functional impairments and increased suicide risk [6]. The lifetime prevalence of
anxiety disorders and substance disorders are estimated at 18.1% and 14.6%, respectively
[7], making the impact of this elevated risk substantial. However, the directionality of these
effects is not clear. Increased comorbidity could be conceptualized as addiction increasing
the likelihood of anxiety (due to drug use or withdrawal [8]), anxiety increasing the
likelihood of addiction (to self-medicate symptoms [9]), or a third factor increasing the risk
of both addiction and anxiety [5]. Disentangling these influences is highly complex, but as a
potential starting point to unpick this relationship, twin and family studies focusing on
alcohol disorders suggest that there may be a shared genetic etiology influencing liability to
both addiction and anxiety [5,10,11].

Author Manuscript

Genetics play an important role in addiction disorders [12]. Heritability estimate for
addiction to specific drugs are well established [13]. Furthermore, twin and family studies
indicate that in addition to substance-specific genetic influences, there are common genetic
factors acting across addiction phenotypes [14–16]. These findings suggest that genetic
liability to addictive disorders arises from an increased propensity to addiction in general,
combined with influences that are specific to that particular drug. Similarly, anxiety
disorders are interlinked with one another, with high comorbidity rates (one study estimates
76% of anxiety cases have a experienced at least one other anxiety or depressive disorder
[17]). We know that anxiety disorders are heritable [18,19], and as with addiction
Eur Psychiatry. Author manuscript; available in PMC 2017 June 26.
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phenotypes, multivariate analyses exploring the genetic relationship between the different
anxiety disorders have been undertaken. Results indicate an important role for common
genetic influences acting across anxiety subtypes in addition to subtype-specific genetic
influences [20–22]. Indeed, Tambs et al. [20] report that that heritability estimates for
liability to any anxiety disorder (including PTSD and OCD) are higher than those for
individual anxiety subtypes. Furthermore, the common genetic influences acting across
anxiety subtypes substantially (but not completely) overlap with the genetic factors
associated with neuroticism [23].

Author Manuscript

The high comorbidity between addictive and anxious phenotypes may reflect shared genetic
influences. Genetics factors contribute substantially to the phenotypic correlations between
alcohol consumption and anxiety or depression symptoms in twins [11]. Furthermore, a
number of studies looking at patterns of transmission in families show shared familial risk
factors for alcohol dependence and panic disorder [5,10], consistent with the hypothesis that
addiction and anxiety are genetically correlated traits. Nevertheless, these studies have
tended to focus on alcohol-related phenotypes; there is less work considering whether this
genetic overlap generalizes across addiction subtypes.

Author Manuscript

To gain insight into the neurobiology underlying the overlap between addiction and anxiety,
it is important to both understand the extent to which genetic liabilities are common among
traits, and identify the genetic loci that contribute to this shared liability. Linkage analysis
within family studies can allow us to do this by identifying chromosomal regions that
segregate in families with disease. Furthermore, linkage methods capture a diverse range of
types of genetic effects, including common and rare variants that are also important
contributors to the risk for psychiatric disorders [24,25]. A number of univariate genomewide linkage efforts have been published exploring anxiety disorders [26], and addiction
[27–29]. While some genes implicated in this comorbidity have been linked separately to the
risk for each disorder using candidate approaches, including neuropeptide Y [30,31] and
GABA [32], we are unaware of any previous studies that have used linkage methods to
investigate the comorbidity of these disorders on a genome-wide scale. Here, we employ
bivariate linkage approaches looking at addiction and anxiety traits together, to identify
chromosomal regions with pleiotropic influences on both traits. Bivariate linkage analysis
provides greater statistical power to detect quantitative trait loci for correlated traits, as well
as improved localization of the linkage signal [33], offering a powerful tool to identify
genomic regions that jointly influence these comorbid disorders. We examine the genetic
influences on addiction and anxiety phenotypes using a large randomly ascertained family
sample and use both univariate and bivariate linkage analyses to identify chromosomal loci
that underpin these phenotypes and their patterns of comorbidity.

Author Manuscript

2. Methods
2.1. Study sample
The sample consisted of 1284 Mexican-Americans from 75 extended pedigrees (containing
2–132 subjects, mean pedigree size = 16.36, SD = 19.41) and an additional 57 genetically
unrelated spouses. The mean age of the sample was 46.08 years (SD = 14.89, range = 18–97
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years), and 62.7% of the sample was female. Stated pedigree relationships were confirmed
using PREST and available autosomal markers [34].
The sample is a subset of the San Antonio Family Study cohort of individuals randomly
ascertained with the constraints that participants must live within the San Antonio region, be
Mexican-American in ancestry, and part of a large family (at least 6 1st degree relatives).
Full recruitment details are available elsewhere [35,36]. All subjects provided informed
written consent (as approved by Institutional Review Boards at the university of Texas,
health science center San Antonio and Yale university) and the cohort have been actively
participating in research for over 18 years.
2.2. Phenotypic assessment

Author Manuscript

The semi-structured Mini International Psychiatric Interview Plus (MINI-Plus; [37]) was
administered to all participants, with additional questions to establish lifetime history of
psychiatric disorders, using DSM-IV criteria [38]. Lifetime history of chronic smoking was
defined as ever having smoked cigarettes, cigars or a pipe every day for a month or more.
Lifetime history of alcohol dependence was assessed, as was drug dependence (here defined
as dependence on any drugs other than tobacco or alcohol; the Supplementary materials
includes the prompts given). Anxiety cases were defined as those patients meeting criteria
for any of the following; panic disorder, agoraphobia, social phobia, specific phobia, OCD,
PTSD, or generalized anxiety disorder. Prevalence by subtype is included in the
Supplementary materials. All interviewers administering the MINI-Plus had a doctorate or
master’s degree in a mental health field or a bachelor’s degree with at least 2 years of
relevant experience, and high levels of diagnostic reliability were reached for anxiety and
addiction disorders (κ > = 0.90).

Author Manuscript

2.3. Genotyping
Genotyping for approximately one million SNPs was performed using Illumina
HumanHap550v3, HumanExon510Sv1, Human1Mv1 and Human1M-Duov3 BeadChips,
and following the Illumina Infinitum protocol. For quality control, SNPs and samples were
removed if < 95% of genotypes were present or if the minor allele was present in less than
10 individuals. Allele frequencies were calculated using maximum likelihood methods to
account for pedigree relationships [39] and SNPs were observed to be in Hardy Weinberg
Equilibrium. SimWalk2 was used to check for Mendelian consistency and missing
genotypes were imputed (utilizing the available pedigree information) within MERLIN [40].

Author Manuscript

For linkage analysis, a subset of 28,387 SNPs from the 1 M GWAS SNPs were selected
using genotypes from 345 founders. SNPS were selected on each chromosome with a
minimum spacing of 1 KB and a minor allele frequency > 5%. To limit linkage
disequilibrium between SNPs, a limit of pairwise r2 < 0.0225 within a 100 kb sliding
window was used. The selected subset of SNPs gave an average of 7–8 SNPs
percentimorgan (cM). Using these 28,387 SNPs, multipoint identity-by-descent matrices
were constructed at each centimorgan location, using a stochastic Markov Chain Monte
Carlo procedure within LOKI [41].

Eur Psychiatry. Author manuscript; available in PMC 2017 June 26.
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SOLAR was used for all genetic analyses [42]. This software uses maximum likelihood
decomposition methods to model the patterns of trait covariance between family members as
a function of genetic relationships, and so estimate the genetic and environmental
contributions to phenotypes within a family structure. All analyses included the covariates of
age, age2, sex and their interactions.

Author Manuscript

To identify the relative contribution of additive genetic and environmental influences for
addiction-related and anxiety traits, univariate variance decomposition was performed,
yielding trait heritability estimates. For each trait showing significant heritability, we
performed genome-wide multipoint linkage analysis, to identify chromosomal loci involved
in the trait of interest. Based on a method derived by Feingold et al. [43], it was previously
established in this sample that a LOD score greater than 2.9 indicates a genome-wide
significant linkage peak, whilst a LOD score over 1.67 is indicative of a suggestive peak
(likely to occur by chance less than once per genome-wide scan) [44]. These LOD scores are
per genome-wide scan, whilst here, we examined four correlated phenotypes (alcohol
dependence, drug dependence, smoking and anxiety). Therefore, using the method outlined
by Cheverud [45] to assess the genetic correlations between traits, we established that the
effective number of traits considered was 2.61.

Author Manuscript

We then explored the genetic relationships between addiction and anxiety. First, we
examined the covariance between each of the three addiction-related traits and anxiety, to
obtain bivariate genetic correlations. Then, for pairs of traits where significant genetic
correlations were observed, bivariate linkage analysis was performed [33]. To enable
comparison with the univariate results, bivariate LOD scores were converted to a one
degree-of-freedom equivalent (based upon the P-value for the two degrees-of-freedom test of
linkage to both traits versus linkage to neither). In order to assess whether bivariate linkage
signals were truly bivariate in nature, nested models were compared to test whether the
model could be explained in the absence of any shared genetic effect; that is where cooccurrence of linkage peaks in the two traits occurred by chance [46]. A confidence interval
of maximum LOD score −1 was defined surrounding each significant linkage peak.

Author Manuscript

To follow up any significant linkage signals, we extracted SNPs that were located within
each significant peak from the full 1 M GWAS SNPs. Using the measured genotype
association (mga) method, where models include the fixed effect of the SNP and random
effects of local and polygenic heritability, individual SNPs were associated traits of interest.
An additive genetic model was assumed, and the first four principal components of the
GWAS data were included as covariates to account for population and admixture
substructure within pedigrees [47]. To test for significance, a likelihood ratio test was
employed, comparing models where the genotype parameter is allowed to vary freely or is
fixed to zero. Given linkage disequilibrium, the pairwise correlations between SNPs were
used to calculate the effective number of independent tests within each region [48], for an
appropriate multiple-testing correction.

Eur Psychiatry. Author manuscript; available in PMC 2017 June 26.
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3. Results
3.1. Univariate analyses
The prevalence and heritability of each trait is shown in Table 1. As expected, for addiction
phenotypes, there are fewer female than male cases, but the majority of anxiety cases are
female. When calculating the heritability of each trait, sex was a significant covariate for all
phenotypes (details are given in the Supplementary materials).

Author Manuscript

Univariate genome-wide linkage scans were performed for each of the four phenotypes
under consideration. Significant linkage peaks were observed for drug dependence on
chromosome 14 at 41cM (LOD score = 3.322) and for anxiety on chromosome 12 at 164cM
(LOD = 2.918). For alcohol dependence and smoking, genome-wide significance was not
reached. The maximum linkage for alcohol dependence was on chromosome 16 at 54cM
(LOD score = 2.752) and for smoking on chromosome 4 at 80cM (LOD score = 2.735). The
maximum peak for every trait is shown in Fig. 1. The Supplementary materials includes
details on the genes located within each of these peaks, as well as plots of genome-wide
linkage results for all four traits. The linkage signal for anxiety on chromosome 12
encompasses TMEM132D, which has previously been associated with anxiety-related traits
[49–53]. Each of the univariate linkage signals is specific to the trait of interest; LOD scores
are below 0.7 for all other traits in each of the identified chromosomal loci.
3.2. Bivariate analyses

Author Manuscript

The patterns of comorbidity between addiction subtypes and anxiety are shown in Table 2
(comorbidity rates amongst the addiction subtypes are in the Supplementary materials).
Patterns of shared genetic underpinnings are evident (Table 3) with significant positive
genetic correlations observed between anxiety and each of the addiction traits.

Author Manuscript

Bivariate linkage scans were performed for anxiety with each of the addiction traits.
Evidence of pleiotropic genomic regions were observed in two cases. For alcohol
dependence and anxiety, a significant bivariate peak was observed on chromosome 9 (at
133cM, LOD = 3.054). At this location, the univariate linkage analyses gave a LOD = 2.562
for alcohol dependence and LOD = 1.673 for anxiety. Using nested models to compare
coincident with pleiotropic models, this peak was observed to be pleiotropic (χ2[1] = 11.38,
p = 3.71 × 10−4). A second significant bivariate linkage peak was observed for drug
dependence and anxiety on chromosome 18 at 29 cm (LOD = 3.425, pleiotropy test χ2[l] =
16.02, p = 3.14 × 10−5). The univariate linkage signals at this locus were LOD = 1.098 for
drug dependence and LOD = 1.887 for anxiety. No significant bivariate linkage was
observed for anxiety and smoking. The significant bivariate linkage peaks are shown in Fig.
2. Genes located within these peaks and plots of the full genome-wide linkage results are in
the Supplementary materials.
3.3. Association analysis of significant linkage peaks
We performed mga analysis using all of the available SNPs underneath each of the four
significant linkage peaks identified. No SNPs reached peak-wide significance, for any of the
four regions considered, although the most significant SNP for anxiety (rs10744424) is
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within TMEM132D. Details of the best performing SNPs for each region are given in Table
4.

4. Discussion
4.1. Summary of findings
We have demonstrated that shared genetic influences play an important role in the high rates
of comorbidity between anxiety and addiction (examining alcohol dependence, drug
dependence and chronic smoking in turn). We observed genetic correlations between 0.550–
0.655 within a Mexican-American extended pedigree sample. This is consistent with
previous findings for anxiety and alcohol dependence [5,10,11] and our genetic correlation
estimates are also similar to those observed when considering addiction in relation to major
depression [54,55].

Author Manuscript
Author Manuscript

Having established a common genetic etiology, we used genome-wide linkage analyses to
identify specific and pleiotropic quantitative trait loci for these phenotypes. Genome-wide
significant univariate linkage signals were observed for drug dependence at 14q13.2–q21.2
and for anxiety at 12q24.32–q24.33. Genomewide significant bivariate linkage peaks were
observed for alcohol dependence-anxiety at 9q33.1–q33.2 and for drug dependence-anxiety
at 18p11.23–p11.22. For each of the phenotypes considered here, the identified quantitative
trait loci were phenotype specific; LOD scores were low (< 0.7) in the univariate linkage
scans of the other traits, despite the high genetic correlations among traits. It suggests that
these loci are phenotype-specific, without pleiotropic effects on the other traits studied.
However, given the limited power to detect loci of small effect, it is also possible that the
loci were detected only through the phenotype on which they exert the largest effect and
potential pleiotropic effects on the other phenotypes cannot be excluded. We used mga
analyses to try to localize these linkage signals, using available SNP data. We were unable to
identify any peak-wide significant SNP associations; this may be as we were only able to
examine common SNPs or possibly due to sample size limitations.
4.2. Previously implicated genomic locations

Author Manuscript

The significant linkage signals identified in this analysis show some interesting convergence
with previous findings in psychiatric genetics. First, in the univariate analysis of anxiety, we
observed a significant linkage peak on chromosome 12q24.32–q24.33. While this peak only
just reaches the threshold for genome-wide significance, it is of particular interest given that
TMEM132D (transmembrane protein 132D) lies within this region. This gene was first
implicated through GWAS investigation of panic disorder, with mouse model evidence
supporting an involvement in anxious behavior [49]. Since then, both common and rare
variants within the gene have been associated with anxiety disorders [50–52] and links have
also been observed between variants in this gene, amygdala volume and anxiety traits in
healthy controls [53]. Using association analysis in this region, the best performing SNP in
our sample is rs10744424 (intronic within TMEM132D), although it does not reach
significance when correcting for all SNPs available in the 2.66MB linkage region.
Therefore, the identification here of a linkage peak for anxiety in the same genomic region
as previous research is consistent with the role of the gene in liability to anxiety disorders,
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but as we are unable to more specifically localize the signal within this peak, our findings
are not conclusive.
Second, we localize a bivariate linkage signal between alcohol dependence and anxiety at
9q33.1–q33.2. Previous work has linked rare CNVs within 9q33 to a number of traits,
including neurodevelopmental delays and psychiatric disorders including anxiety [56]. There
has also been some evidence of linkage in this region with addiction traits; in a study of
alcohol-related traits a suggestive linkage peak was observed in the same location [57] and
in a 2008 review of genome-wide linkage studies in smoking, this region had been
implicated in four independent samples [58], although this signal was not observed in a later
meta-analysis [27] and the signal has not been localized to a specific gene. Therefore, there
is some tentative evidence that this genomic region may be linked to liability to a number of
psychiatric traits.

Author Manuscript

The remaining linkage peaks (for drug dependence on chromosome 14 and for drug
dependence-anxiety on chromosome 18) identified in this study appear to be in regions that
have not previously been highlighted in addiction genetics. Generally, for illicit drugs, the
genetic loci involved are not well established, which may in part be due to the difficulties in
obtaining sufficiently large samples of drug dependent individuals for adequately powered
genetic studies. Indeed, the drug dependent group contains individuals that are addicted to a
range of different illicit drugs (such as cannabis, cocaine or tranquilizers). By grouping these
individuals into a single category, we are able to increase statistical power to detect genetic
effects that are common among these illicit drugs and detect both univariate and pleiotropic
linkage signals, although drug-specific signals may be obscured.
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It is of note that we did not observe genome-wide linkage signals within either univariate or
bivariate models for smoking within this sample, using an “ever vs never” categorization to
assess initiation of chronic smoking. This is despite significant trait heritability (h2 = 0.554)
and genetic correlation with anxiety (ρg = 0.550). There has been greater success in the
literature using smoking quantity or nicotine dependence phenotypes, which are genetically
overlapping but not identical to smoking initiation [59]. However, these measures are
unavailable in this sample. In a comprehensive meta-analysis of linkage studies looking at
3404 families, genome-wide significance was only observed with the phenotype of
“maximum number of cigarettes per day”, on chromosome 20q13.12–13.32 [27].
Interestingly, in this metaanalysis, they failed to find evidence on linkage on chromosome
15q25, the location of the nicotinic acetylcholine receptor gene cluster which is a wellestablished hit for the phenotype of “cigarettes per day” from genome-wide association
approaches [60].

Author Manuscript

4.3. Implications of findings
As a complex trait, addiction is likely to be highly polygenic, with both general and
substance-specific components; the genetic loci identified to date only account for a small
proportion of the variance in liability to addiction. Similarly, the genetic influences on
anxiety traits remain poorly understood. By considering the relationships between addiction
and anxiety, we aimed to reveal details of the genetic architecture underlying these comorbid
traits. By demonstrating genetic correlations between addiction subtypes and anxiety, we
Eur Psychiatry. Author manuscript; available in PMC 2017 June 26.

Hodgson et al.

Page 9

Author Manuscript

have shown that shared genetic etiology plays an important role in the high rates of
comorbidity, although this does not exclude the existence of causal pathways between the
two types of disorder. It still remains that addiction could manifest as a result of anxiety
symptoms, or indeed vice versa. We suggest that a single generality is unlikely,
heterogeneity between individuals and a pattern of multiple interacting pathways fits the
diverse clinical picture more accurately. However, to begin to understand the biological
pathways responsible for the shared genetic etiology of these two disorders, we must
identify the specific genes involved.

Author Manuscript

Leveraging the increased statistical power of bivariate linkage analyses to identify the
regions of the genome involved in this shared genetic etiology [33], we have highlighted
potential pleiotropic regions of the genome, implicating both previously identified and novel
chromosomal loci that may contribute risk for each these diagnoses. These regions point to
candidates for further research into these disorders, and offer a potential starting point to
begin to unpick the underlying neurobiology for each diagnosis and understand how they
might be interconnected.
4.4. Characteristics of the sample

Author Manuscript

Our study examines a Mexican-American sample. Within the USA, it has been shown that
the prevalence of addiction and psychiatric disorders in amongst Hispanics is generally
lower than amongst non-Hispanic Caucasians; this is also true for black and Asians
minorities [7,61]. However, there is variation within ethnic minority subgroups, according to
interacting factors including country of origin, level of discrimination and acculturation [62–
65]. Relating the prevalence of disorder within the sample to US national averages, we find
that addiction phenotypes are more common in this sample, however, rates of anxiety are
comparable to those reported in large epidemiological surveys [7,61].

Author Manuscript

In defining anxiety in this sample, we grouped all anxiety diagnoses along with PTSD and
OCD together into a single category. This approach of grouping rather than splitting was
taken for two reasons; first due to low numbers of cases for some diagnoses. Second, whilst
this grouping does not capture known anxiety disorder-specific genetic influences, previous
work shows that when all anxiety disorders (including PTSD and OCD) are considered, a
common pathway model best describes the relationship between disorders, with most of the
genetic effects being shared across disorders [20]. Additional epidemiological [66] and twin
[21] research supports this approach. Whilst we relied upon DSM-IV criteria [38] to classify
alcohol dependence, substance dependence and anxiety disorders, we note that in DSM-V
[67] (published after the collection of this data), OCD and PTSD have been moved from the
Anxiety Disorders chapter (to adjacent chapters of Obsessive-Compulsive and Related
Disorders and Trauma and Stressor-Related Disorders) and changes have been made to
criteria defining substance use disorders.
It is known that patients recruited into a study from a treatment setting often differ from the
general population of affected individuals, particularly in terms of symptom severity and
patterns of comorbidity [68]. By using a randomly ascertained extended pedigree sample, we
have side-stepped these potential biases. Additionally, the extended pedigree design that we
employ here offers increased power to detect quantitative trait loci over smaller family units
Eur Psychiatry. Author manuscript; available in PMC 2017 June 26.
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in most circumstances [69], and while family studies typically do not directly estimate the
influence of environments shared by family members (as twin studies do), the inflation of
heritability estimates by these shared environmental influences are much less likely in
multigenerational families such as those included in this sample [70].
Given the contrasting prevalence by sex of addiction and anxiety, paired with overlapping
genetic liability, the manifestation of symptoms associated with this shared vulnerability
may differ by gender. It would be of interest to model genetic liability to these comorbidity
disorders in a sex-specific manner. However, this sample is not well suited to tackle the
issue, as sex-specific analyses would require breaking up the extended pedigree structure,
resulting in a substantial loss of statistical power and further, only autosomal chromosomes
are considered in this analysis.

Author Manuscript

5. Conclusions
In this study, we observe a number of significant quantitative trait loci that underlie the
genetic overlap of the addiction subtypes of alcohol dependence, drug dependence and
smoking with anxiety, within a randomly ascertained sample. The regions we identify show
some convergence with previous literature, but also highlight a number of novel genomic
loci involved in the comorbidity of these psychiatric traits.
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Fig. 1.

Signficant univariate linkage signals. Alcohol dependence (Chr 16LOD = 2.752 at 54cM);
drug dependence (Chr 14LOD = 3.322 at 41cM); smoking (Chr 4 LOD = 2.735 at 80cM);
anxiety (Chr 12 LOD = 2.918 at 164cM).
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Fig. 2.

Significant bivariate linkage signals. Alcohol dependence and anxiety (Chr 9 at 133cM,
bivariate LOD = 3.054); drug dependence and anxiety (Chr 18 at 29cM, bivariate LOD =
3.425). Bivariate linkage shown in grey, overlaid on univariate signals.
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(n = 294)

Anxiety
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Drug dependence
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% cases
(total n =1284)

Trait
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h2
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P-value

Heritability
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Table 2
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Addiction cases with comorbid anxiety.
Percentage of cases with comorbid anxiety
Alcohol dependence

28.3%
(n = 85)

Drug dependence

38.2%
(n = 52)

Smoking

22.5%
(n=98)
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Table 3

Author Manuscript

Phenotypic and genetic correlations between addiction traits and anxiety.
Phenotypic correlation with anxiety

Genetic correlation with anxiety

Alcohol dependence

0.281
(P=1.85E-06)

0.655
(P=3.48E-03)

Drug dependence

0.412
(P=2.75E-09)

0.619
(P=7.82E-03)

Smoking

0.112
(P=4.15E-02)

0.550
(P=3.73E-03)
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Table 4

Author Manuscript

Best performing snps in association analysis. No snps pass peak-wide significance.
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Drug dependence

Anxiety

Alcohol dependence/anxiety

Drug dependence/anxiety

Chromosome

14

12

9

18

Size of linkage peak region
(Mb)

8.46

2.66

4.98

1.20

No. of SNPs in peak

2728

1443

1643

552

Effective no. of SNPs in peak

1364.97

952.619

898.131

337.16

Peak-wide P-value threshold

3.76E-05

5.38E-05

5.71E-05

1.52E-04

Min P-value observed

2.62E-04

7.80E-05

1.30E-04

2.27E-03

Best SNP

rs17113722

rs10744424

rs10117151

rs11661395

Alleles

C/T

A/G

A/C

C/T

SNP MAF

0.052

0.117

0.433

0.478

Allele frequency in 1000
genomes MXL population

0.070

0.133

0.469

0.523

Allele frequency in 1000
genomes EUR population

0.082

0.156

0.625

0.416

Allele frequency in Alfred Pima
Bajo population

0.020

0.000

0.120

Not available

Nearest gene

LRFN5 (nearest)

TMEM132D (intronic)

ASTN2 (nearest)

RAB12 (nearest)
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